Skip to content

Erzhiwan Jiawei in treating early and middle stage knee osteoarthritis of kidney deficiency and blood stasis: A prospective, single center, double-blind, randomized controlled trial

Erzhiwan Jiawei in treating early and middle stage knee osteoarthritis of kidney deficiency and blood stasis: A prospective, single center, double-blind, randomized controlled trial

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400084133
Enrollment
Unknown
Registered
2024-05-11
Start date
2024-06-01
Completion date
Unknown
Last updated
2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee Osteoarthritis

Interventions

Treatment group:conventional treatment+oral granules of Erzhiwan Jiawei
Control group:conventional treatment+oral placebo

Sponsors

First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: ? Those who meet the diagnostic criteria for Western medicine and traditional Chinese medicine syndromes mentioned above; ? Age range from 18 to 75 years old; ? Patients who have not undergone knee joint surgery in the past, have not received KOA related treatment in the past month, or have a washout period of at least 14 days after receiving treatment; ? For those with K-L imaging grades of I-III, X-ray grading shall refer to the K-L imaging grading method; ? Voluntarily participate and sign an informed consent form to cooperate with follow-up; ? The onset of knee osteoarthritis in the patient is unilateral knee joint.

Exclusion criteria

Exclusion criteria: ? Knee joint swelling and fever; ? Metabolic bone disease and chronic severe disease caused by endocrine disorders; ? Pregnant, pre pregnancy or lactating women, as well as mentally ill patients; ? Individuals who have received glucocorticoid treatment or knee arthroscopy within the past 2 months; ? Individuals who have suffered knee injuries or undergone surgical procedures within the past 6 months; ? Individuals who are allergic to any component of the investigational drug; ? Congenital knee joint developmental abnormalities or vascular and nerve injuries; ? Patients with significantly narrowed knee joint space that meets surgical indications; ? Those who are unable to use medication and receive treatment according to regulations, have poor compliance, cannot determine the efficacy or incomplete treatment, which affects the efficacy and safety judgment; ? Individuals who have participated or are currently participating in other clinical trials within the past month. Note: Patients who meet any of the above criteria will be excluded from the study scope.

Design outcomes

Primary

MeasureTime frame
Western Ontario and McMaster Osteoarthritis Index;

Secondary

MeasureTime frame
Lysholm;VAS;Knee joint range of motion;TCM syndrome score;Criteria for the therapeutic effect of TCM syndromes;Knee joint ultrasound;Knee joint MRI;hepatic and renal function;Blood routine;Incidence of adverse events;Serum inflammatory factors;

Countries

China

Contacts

Public ContactLiu Aifeng

First Teaching Hospital of Tianjin University of Traditional Chinese Medicine

draifeng@163.com+86 138 0309 1533

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026